NCT04833387View on ClinicalTrials.gov

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Colorectal Carcinoma
Interventions
DRUG

PD-1 antibody

Capecitabine:Dose of 1650mg/m2,14days; Radiation:50Gy/25 fractions;IBI308: 200mg on day1 of each cycle, 3 cycles; Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR)

Trial Locations (1)

510060

651 Dongfeng Road East, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

collaborator

Liaoning Cancer Hospital & Institute

OTHER

collaborator

Fudan University

OTHER